235 related articles for article (PubMed ID: 21368231)
21. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.
Marckmann S; Wiesemann E; Hilse R; Trebst C; Stangel M; Windhagen A
Clin Exp Immunol; 2004 Dec; 138(3):499-506. PubMed ID: 15544628
[TBL] [Abstract][Full Text] [Related]
22. IFN-β induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis.
Chen M; Chen G; Deng S; Liu X; Hutton GJ; Hong J
J Neuroimmunol; 2012 Jan; 242(1-2):39-46. PubMed ID: 22112394
[TBL] [Abstract][Full Text] [Related]
23. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
[TBL] [Abstract][Full Text] [Related]
24. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism.
Azoulay D; Mausner-Fainberg K; Urshansky N; Fahoum F; Karni A
J Neuroimmunol; 2009 Jun; 211(1-2):114-9. PubMed ID: 19419774
[TBL] [Abstract][Full Text] [Related]
25. Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis.
Peng X; Jin J; Giri S; Montes M; Sujkowski D; Tang Y; Smrtka J; Vollmer T; Singh I; Markovic-Plese S
J Neuroimmunol; 2006 Sep; 178(1-2):130-9. PubMed ID: 16870268
[TBL] [Abstract][Full Text] [Related]
26. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
27. Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis.
Miyazaki Y; Iwabuchi K; Kikuchi S; Fukazawa T; Niino M; Hirotani M; Sasaki H; Onoé K
Mult Scler; 2008 Sep; 14(8):1044-55. PubMed ID: 18573819
[TBL] [Abstract][Full Text] [Related]
28. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis.
Stasiolek M; Bayas A; Kruse N; Wieczarkowiecz A; Toyka KV; Gold R; Selmaj K
Brain; 2006 May; 129(Pt 5):1293-305. PubMed ID: 16513684
[TBL] [Abstract][Full Text] [Related]
29. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
[TBL] [Abstract][Full Text] [Related]
30. Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis.
Zhang X; Tao Y; Wang J; Garcia-Mata R; Markovic-Plese S
Eur J Immunol; 2013 Jan; 43(1):281-9. PubMed ID: 23076801
[TBL] [Abstract][Full Text] [Related]
31. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.
Zafranskaya M; Oschmann P; Engel R; Weishaupt A; van Noort JM; Jomaa H; Eberl M
Immunology; 2007 May; 121(1):29-39. PubMed ID: 17239199
[TBL] [Abstract][Full Text] [Related]
32. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
[TBL] [Abstract][Full Text] [Related]
33. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
34. Interferon-β treatment normalises the inhibitory effect of serum from multiple sclerosis patients on oligodendrocyte progenitor proliferation.
Kotsiari A; Voss EV; Pul R; Skripuletz T; Ragancokova D; Trebst C; Stangel M
Neurosci Lett; 2010 Nov; 485(2):107-11. PubMed ID: 20816724
[TBL] [Abstract][Full Text] [Related]
35. Interferon-beta induces the development of type 2 dendritic cells.
Huang YM; Hussien Y; Yarilin D; Xiao BG; Liu YJ; Link H
Cytokine; 2001 Mar; 13(5):264-71. PubMed ID: 11243704
[TBL] [Abstract][Full Text] [Related]
36. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients.
Kümpfel T; Schwan M; Pollmächer T; Yassouridis A; Uhr M; Trenkwalder C; Weber F
Mult Scler; 2007 Nov; 13(9):1138-45. PubMed ID: 17967841
[TBL] [Abstract][Full Text] [Related]
37. Interferon-beta inhibits Th1 responses at the dendritic cell level. Relevance to multiple sclerosis.
Bartholomé EJ; Willems F; Crusiaux A; Thielemans K; Schandené L; Goldman M
Acta Neurol Belg; 1999 Mar; 99(1):44-52. PubMed ID: 10218092
[TBL] [Abstract][Full Text] [Related]
38. Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b.
Speciale L; Saresella M; Caputo D; Ruzzante S; Mancuso R; Calvo MG; Guerini FR; Ferrante P
J Neurovirol; 2000 May; 6 Suppl 2():S57-61. PubMed ID: 10871787
[TBL] [Abstract][Full Text] [Related]
39. IL-6 produced by type I IFN DC controls IFN-gamma production by regulating the suppressive effect of CD4+ CD25+ regulatory T cells.
Detournay O; Mazouz N; Goldman M; Toungouz M
Hum Immunol; 2005 May; 66(5):460-8. PubMed ID: 15935883
[TBL] [Abstract][Full Text] [Related]
40. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
